At a glance
This program funds early-stage, high-risk lung cancer research that could lead to major discoveries, and it must address at least one FY26 Lung Cancer Research Program area of emphasis. U.S. Department of War organizations, including foreign and domestic, for-profit and nonprofit, and public or private entities, may apply, and the principal investigator may be an independent investigator at any career level or a new investigator within 10 years of first faculty appointment who has not previously received this award. The program expects to fund about eight awards, with total costs capped at $800,000 per award and a maximum period of performance of 3 years. Cost sharing is not required. Clinical trials are not allowed, mesothelioma-only applications will not be accepted, and painful research involving domestic cats or dogs is not supported except for studies relating to military or service animals.
What it funds
Official description from grants.gov
Summary: The fiscal year 2026 (FY26) Lung Cancer Research Program (LCRP) Idea Development Award (IDA) supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from lung cancer. This mechanism promotes new ideas that are in the early stages of development and have the potential to yield impactful data and new avenues of investigation. Research must address at least one of the FY26 LCRP areas of emphasis. Distinctive Features: This FY26 LCRP IDA mechanism has a New Investigator category that is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators. Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of lung cancer.
Who can apply
- Unrestricted